LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

78.61 -3.47

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

78.23

Max

81.24

Galvenie mērījumi
By Trading Economics
Ienākumi	-252M -129M
Pārdošana	-295M 157M
EPS	-0.613
Peļņas marža	-82.062
Darbinieki	1,069
EBITDA	-245M -94M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+4.37% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.6B 13B
Iepriekšējā atvēršanas cena	82.08
Iepriekšējā slēgšanas cena	78.61

Ziņu noskaņojums

By Acuity

34%

66%

91 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. dec. 23:48 UTC

Galvenie tirgus virzītāji

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

2025. g. 8. dec. 23:44 UTC

Tirgus saruna

Perky Australian Dollar Looks to Extend Gains -- Market Talk

2025. g. 8. dec. 23:42 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

2025. g. 8. dec. 23:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. dec. 23:13 UTC

Tirgus saruna

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

2025. g. 8. dec. 23:09 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

2025. g. 8. dec. 22:46 UTC

Tirgus saruna

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

2025. g. 8. dec. 22:01 UTC

Tirgus saruna

Miners Poised to Do Well in 2026 -- Market Talk

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

2025. g. 8. dec. 21:51 UTC

Tirgus saruna

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 8. dec. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

2025. g. 8. dec. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

2025. g. 8. dec. 21:36 UTC

Tirgus saruna

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

2025. g. 8. dec. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

2025. g. 8. dec. 21:12 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025. g. 8. dec. 21:08 UTC

Tirgus saruna

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

2025. g. 8. dec. 20:38 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

2025. g. 8. dec. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025. g. 8. dec. 20:18 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

2025. g. 8. dec. 20:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 8. dec. 20:06 UTC

Tirgus saruna

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

2025. g. 8. dec. 20:05 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. dec. 20:05 UTC

Tirgus saruna

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

2025. g. 8. dec. 20:01 UTC

Tirgus saruna

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

4.37% augšup

Prognoze 12 mēnešiem

Vidējais 85.07 USD 4.37%

Augstākais 110 USD

Zemākais 65 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

91 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.